<DOC>
	<DOCNO>NCT02290301</DOCNO>
	<brief_summary>The primary objective study investigate cardiovascular safety gemigliptin evaluating time patient report major adverse cardiovascular event ( MACE ) T2DM patient treat gemigliptin . Study patient follow 4 year MACE occurrence patient drop study completion study . The patient switch non-gemigliptin treatment initiate gemigliptin therapy follow MACE occurrence patient drop study completion study . The secondary objective study evaluate adverse event relate well not-related MACE diabetic patient treat gemigliptin .</brief_summary>
	<brief_title>An Observational Study Evaluate Cardiovascular Outcomes T2DM PatientsTreated With Gemigliptin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Female male patient , â‰¥ 19 year , diagnosis T2DM Diabetic patient whose condition adequately control ongoing dietary and/or antidibatetic treatment decide prescribe gemigliptin accord physician 's judgment Patients must willing able provide write informed consent form use personal information well guardian 's contact information permission contact guardian case patient contact . Patients T1DM Patients experienced acute coronary syndrome ( STelevation myocardial infarction non ST elevation myocardial infarction ) ischemic stroke within last 3 month enrolment OR patient treat dipeptidyl peptidase IV ( DPP4 ) inhibitor glucagonlike peptide ( GLP1 ) analogues 3 month enrolment . Patients diagnosis severe endstage heart failure ( New York Heart Association class III IV ) . Patients currently participate plan participate interventional clinical trial Patients prescribe gemigliptin counterindications gemigliptin Patients consider fit study physician</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>